Novartis says its new gene therapy Zolgensma (onasemnogene abeparvovec- xioi) has coverage policies from payers representing 40% of commercial lives, and high profile news reports name Aetna Inc. and Anthem, Inc. among insurers expanding their policies to cover more patients. That’s despite a $2.125 million price tag and a mere two months on the market — and comes amid a harsh rebuke from the FDA over news that Novartis subsidiary AveXis, Inc. hid some data during the agency’s review process.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.